2-CHLORODEOXYADENOSINE (2CDA) FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS

2-氯脱氧腺苷 (2CDA) 治疗慢性进行性多发性硬化症

• 批准号: 6307369
• 负责人: JACK C SIPE
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307369
• 关键词: artificial immunosuppression; chlorodeoxyadenosine; clinical research; drug screening /evaluation; human subject; human therapy evaluation; immunosuppressive; multiple sclerosis; nervous system disorder chemotherapy; placebos

Multiple sclerosis (MS) is a progressive neurologic disorder that is likely to have an autoimmune basis. We have been testing the safety and efficacy of cladribine (2-CdA) as a treatment for MS. Other current treatments are unsatisfactory, with Beta Interferon and Copaxone having a partial effect on relapses in MS. We have completed treatment trials in chronic progressive MS and have shown that cladribine, an immunosuppressive agent, retards the progression of the disease for two years or longer. A double-blind, placebo-controlled clinical trial of cladribine in relapsing-remitting MS (subproject #288) has just been completed.

多发性硬化症(MS)是一种进行性神经系统疾病，可能有自身免疫基础。我们一直在测试克拉三滨(2-CDA)作为治疗多发性硬化症的安全性和有效性。其他目前的治疗方法并不令人满意，贝塔干扰素和Copaxone对多发性硬化症的复发有部分效果。我们已经完成了对慢性进展性多发性硬化症的治疗试验，并表明免疫抑制剂克拉三滨可以将疾病的进展延迟两年或更长时间。一项双盲、安慰剂对照的克拉曲滨治疗复发-缓解型多发性硬化症的临床试验(子项目#288)刚刚完成。